Dabrafenib A Targeted Therapy pro BRAF-mutated Cancer

II. Indicationes clinicae:

A. Monotherapy:

Unresectable vel metastatic melanoma cum BRAF V600E mutationem

B. deducto therapia cum trametinib:

BRAF V600E-positivum unresectable vel metastatic melanoma

Cancer metastaticus pulmonis cellula non-parva

Cancer metastaticus anaplastic thyroideum

Aut solida metastatic tumores unresectable

III. Mechanismus Actionis:

A. De ligatione et inhibitione selectiva B-raf

B. Inhibitio tumoris cellulae multiplicationis cum BRAF gene mutatis

IV. Curatio Cancri thyroideae:

A. Genus quoddam cancri thyroideae, quod ad fibras proximas vel alias partes corporis diffusa est

B. Previous treatment (s) resistentia

V. Kinase Inhibitor Classis:

A. Dabrafenib membrum kinasi inhibitores

B. Clausus alius dapibus actionis ne multiplicatio cancer cellularum